Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

3M NAD case

This article was originally published in The Tan Sheet

Executive Summary

The National Advertising Division of the Council of Better Business Bureaus announces Nov. 30 it recommends 3M Company modify or discontinue a consumer-preference claim for Nexcare Comfort Ultra Fabric brand adhesive bandages. The Nexcare product claims it is "Preferred #1 in User Test" with the disclosure "Nexcare Comfort Bandages compared to BAND-AID Plastic Comfort-Flex and Sheer Comfort-Flex Bandages and CURAD Plastic and Sheer Bandages." NAD says "even if the objects chosen for the comparison are appropriate and the size and placement of the disclosure is adequate, the claim #1 is likely to be misleading" since Nexcare is not number one in sales or preference. 3M has since discontinued the ads and says "while we respectfully disagree with several findings in the decision, we do respect and support the self-regulatory process and will consider all of NAD's recommendations in future advertising"...

You may also be interested in...



Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 

In US, Market Exclusivity For NDI Notifications ‘Just Not There’ In DSHEA Regulation

Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.

Topics

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel